Healthcare >> CEO Interviews >> November 18, 2002

Harry Dugger Iii – Novadel Pharma Inc (nvdl)

HARRY A. DUGGER III is the President and Chief Executive Officer of NovaDel Pharma Inc. (formerly Flemington Pharmaceutical Corporation). Dr. Dugger is the founder of Flemington Pharmaceutical and the inventor of the lingual spray and bite capsule technology, which the company is developing and marketing as Immediate-Immediate Release (I2R). Dr. Dugger received his PhD from the University of Michigan and was an NIH Postdoctoral Fellow at the University Of Zurich, working on the chemical structure of the colors in red beets and on pseudo-aromatic compounds. He joined Sandoz Pharmaceuticals in the US in 1964, where he was responsible for drug development primarily in the areas of biopharmaceuticals and drug metabolism. In 1980, he resigned to join Baurs-Krey Associates in New York, and in 1982 he founded Pharmaconsult, the precursor to Flemington. Through Pharmaconsult, Dr. Dugger advised clients on all aspects of drug development, including but not limited to manufacturing of drug substances and drug products (cGMP), toxicity studies, clinical trials, filing of ANDAs, INDs, NDAs, as well as co-founding LAB Inc. in the US to market the clinical services of LAB GmbH (Germany) to US-based pharmaceutical companies. Since 1996, Dr. Dugger has spent much of his time in developing a number of I2R formulations and running studies to demonstrate their utility. Profile
TWST: Could you give us an historical sketch of NovaDel Pharma

and bring us up to date on some of the most important things that

you've done lately?

Dr. Dugger: NovaDel started in 1982 as a